Sphingosine 1-phosphate signaling axis mediates neuropeptide S-induced invasive phenotype of endometriotic cells.
Matteo PrisinzanoCaterina BernacchioniIsabelle SeiditaMargherita RossiMaryam RaeispourFrancesca CencettiSilvia VannucciniMassimiliano FambriniFelice PetragliaPaola BruniChiara DonatiPublished in: The FEBS journal (2024)
Endometriosis is a chronic gynecological syndrome characterized by endometrial cell invasion of the extra-uterine milieu, pelvic pain and infertility. Treatment relies on either symptomatic drugs or hormonal therapies, even though the mechanism involved in the onset of endometriosis is yet to be elucidated. The signaling of sphingolipid sphingosine 1-phosphate (S1P) is profoundly dysregulated in endometriosis. Indeed, sphingosine kinase (SK)1, one of the two isoenzymes responsible for S1P biosynthesis, and S1P 1 , S1P 3 and S1P 5 , three of its five specific receptors, are more highly expressed in endometriotic lesions compared to healthy endometrium. Recently, missense coding variants of the gene encoding the receptor 1 for neuropeptide S (NPS) have been robustly associated with endometriosis in humans. This study aimed to characterize the biological effect of NPS in endometriotic epithelial cells and the possible involvement of the S1P signaling axis in its action. NPS was found to potently induce cell invasion and actin cytoskeletal remodeling. Of note, the NPS-induced invasive phenotype was dependent on SK1 and SK2 as well as on S1P 1 and S1P 3 , given that the biological action of the neuropeptide was fully prevented when one of the two biosynthetic enzymes or one of the two selective receptors was inhibited or silenced. Furthermore, the RhoA/Rho kinase pathway, downstream to S1P receptor signaling, was found to be critically implicated in invasion and cytoskeletal remodeling elicited by NPS. These findings provide new information to the understanding of the molecular mechanisms implicated in endometriosis pathogenesis, establishing the rationale for non-hormonal therapeutic targets for its treatment.
Keyphrases
- high glucose
- induced apoptosis
- oxide nanoparticles
- diabetic rats
- polycystic ovary syndrome
- protein kinase
- copy number
- clinical trial
- chronic pain
- cell migration
- type diabetes
- tyrosine kinase
- dna methylation
- pain management
- combination therapy
- gene expression
- neuropathic pain
- endoplasmic reticulum stress
- endothelial cells
- transcription factor
- autism spectrum disorder
- cell proliferation
- adipose tissue
- signaling pathway
- replacement therapy